mTOR/HDAC-IN-1 

mTOR/HDAC-IN-1 (Compound 50) is a selective mTOR and HDAC dual inhibitor with IC₅₀ values of 0.49 and 0.91 nM against mTOR and HDAC1, respectively. mTOR/HDAC-IN-1 can be studied as an anti-cancer agent^[1].

mTOR/HDAC-IN-1 (Compound 50) (0-10 μM, 72 h) shows remarkable anti-proliferative activity against A549, HCT116, and MV4-11 cells^[1].
mTOR/HDAC-IN-1 (0-3 μM, 6 h) simultaneous modulates mTOR signaling and HDAC catalytic activity at cellular level^[1].
mTOR/HDAC-IN-1 displays excellent specificity over both HDAC6 and HDAC11 (with IC₅₀ values of 0.91, 86, 27, and >1000 against HDAC1, HDAC6, HDAC8 and HDAC11) ^[1].
mTOR/HDAC-IN-1 maintains the interaction of MLN0128 with the ATP-binding site in mTOR and binds with the catalytic channel in HDAC^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

501.50

C₂₃H₂₃N₁₁O₃

2815286-02-1

NC1=C(C(C2=CC=C(OC(N)=N3)C3=C2)=N4)C(N4CC(CC5)CCN5C6=NC=C(C(NO)=O)C=N6)=NC=N1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Mingming Zhang, et al. Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy. Bioorg Med Chem Lett. 2021 Oct 1;49:128286.  [Content Brief]